Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation

P. Tosi, S. Ronconi, E. Zamagni, C. Cellini, T. Grafone, D. Cangini, S. A. Pileri, M. Baccarani, S. Tura, M. Cavo

Research output: Contribution to journalArticle

Abstract

Background and Objectives. The introduction of high-dose therapy with stem cell support has significantly improved the outcome of patients with multiple myeloma (MM) in terms of increased complete remission (CR) rate extended survival both disease-free overall. Few options however are presently available for patients who relapse after single or double autologous stem cell transplantation (SCT). Thalidomide a glutamic acid derivative with anti-angiogenetic properties has been recently proposed as salvage treatment for such patients. The present study was aimed at evaluating thalidomide as single agent therapy for patients who had previously received autologous peripheral blood stem cell transplantation. Design Methods. From October 1999 to August 2000 11 patients (7 males/4 females) who had relapsed after single (n=4) or double (n=7) autologous peripheral blood SCT were enrolled in the trial. Thalidomide always employed as a single agent was initially administered at a dose of 100 mg/day; if well tolerated the dose was increased serially by 200 mg every other week to a maximum of 800 mg/day. Results. The median administered dose was 600 mg/day. WHO grade > II toxic effects were constipation lethargy leukopenia. Four patients (36%) showed > 50% reduction in serum M protein concentration 4 showed > 25% reduction for a total response rate averaging 72%. After a median follow-up of 5 months 3 out of 8 responding patients are alive and progression-free and 5 patients have relapsed. Interpretation and Conclusions. These data confirm that thalidomide is active in poor-prognosis MM patients such as those relapsing after autologous SCT, and could thus deserve further testing in combination therapy.

Original languageEnglish
Pages (from-to)409-413
Number of pages5
JournalHaematologica
Volume86
Issue number4
Publication statusPublished - 2001

Fingerprint

Peripheral Blood Stem Cell Transplantation
Salvage Therapy
Thalidomide
Multiple Myeloma
Stem Cell Transplantation
Glutamates
Lethargy
Poisons
Leukopenia
Proxy
Constipation
Disease-Free Survival
Blood Proteins
Stem Cells
Therapeutics
Recurrence

Keywords

  • Autologous stem cell transplantation
  • Multiple myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. / Tosi, P.; Ronconi, S.; Zamagni, E.; Cellini, C.; Grafone, T.; Cangini, D.; Pileri, S. A.; Baccarani, M.; Tura, S.; Cavo, M.

In: Haematologica, Vol. 86, No. 4, 2001, p. 409-413.

Research output: Contribution to journalArticle

Tosi, P, Ronconi, S, Zamagni, E, Cellini, C, Grafone, T, Cangini, D, Pileri, SA, Baccarani, M, Tura, S & Cavo, M 2001, 'Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation', Haematologica, vol. 86, no. 4, pp. 409-413.
Tosi, P. ; Ronconi, S. ; Zamagni, E. ; Cellini, C. ; Grafone, T. ; Cangini, D. ; Pileri, S. A. ; Baccarani, M. ; Tura, S. ; Cavo, M. / Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. In: Haematologica. 2001 ; Vol. 86, No. 4. pp. 409-413.
@article{1832a5fb07c244c9be1571db980afa2c,
title = "Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation",
abstract = "Background and Objectives. The introduction of high-dose therapy with stem cell support has significantly improved the outcome of patients with multiple myeloma (MM) in terms of increased complete remission (CR) rate extended survival both disease-free overall. Few options however are presently available for patients who relapse after single or double autologous stem cell transplantation (SCT). Thalidomide a glutamic acid derivative with anti-angiogenetic properties has been recently proposed as salvage treatment for such patients. The present study was aimed at evaluating thalidomide as single agent therapy for patients who had previously received autologous peripheral blood stem cell transplantation. Design Methods. From October 1999 to August 2000 11 patients (7 males/4 females) who had relapsed after single (n=4) or double (n=7) autologous peripheral blood SCT were enrolled in the trial. Thalidomide always employed as a single agent was initially administered at a dose of 100 mg/day; if well tolerated the dose was increased serially by 200 mg every other week to a maximum of 800 mg/day. Results. The median administered dose was 600 mg/day. WHO grade > II toxic effects were constipation lethargy leukopenia. Four patients (36{\%}) showed > 50{\%} reduction in serum M protein concentration 4 showed > 25{\%} reduction for a total response rate averaging 72{\%}. After a median follow-up of 5 months 3 out of 8 responding patients are alive and progression-free and 5 patients have relapsed. Interpretation and Conclusions. These data confirm that thalidomide is active in poor-prognosis MM patients such as those relapsing after autologous SCT, and could thus deserve further testing in combination therapy.",
keywords = "Autologous stem cell transplantation, Multiple myeloma, Thalidomide",
author = "P. Tosi and S. Ronconi and E. Zamagni and C. Cellini and T. Grafone and D. Cangini and Pileri, {S. A.} and M. Baccarani and S. Tura and M. Cavo",
year = "2001",
language = "English",
volume = "86",
pages = "409--413",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation

AU - Tosi, P.

AU - Ronconi, S.

AU - Zamagni, E.

AU - Cellini, C.

AU - Grafone, T.

AU - Cangini, D.

AU - Pileri, S. A.

AU - Baccarani, M.

AU - Tura, S.

AU - Cavo, M.

PY - 2001

Y1 - 2001

N2 - Background and Objectives. The introduction of high-dose therapy with stem cell support has significantly improved the outcome of patients with multiple myeloma (MM) in terms of increased complete remission (CR) rate extended survival both disease-free overall. Few options however are presently available for patients who relapse after single or double autologous stem cell transplantation (SCT). Thalidomide a glutamic acid derivative with anti-angiogenetic properties has been recently proposed as salvage treatment for such patients. The present study was aimed at evaluating thalidomide as single agent therapy for patients who had previously received autologous peripheral blood stem cell transplantation. Design Methods. From October 1999 to August 2000 11 patients (7 males/4 females) who had relapsed after single (n=4) or double (n=7) autologous peripheral blood SCT were enrolled in the trial. Thalidomide always employed as a single agent was initially administered at a dose of 100 mg/day; if well tolerated the dose was increased serially by 200 mg every other week to a maximum of 800 mg/day. Results. The median administered dose was 600 mg/day. WHO grade > II toxic effects were constipation lethargy leukopenia. Four patients (36%) showed > 50% reduction in serum M protein concentration 4 showed > 25% reduction for a total response rate averaging 72%. After a median follow-up of 5 months 3 out of 8 responding patients are alive and progression-free and 5 patients have relapsed. Interpretation and Conclusions. These data confirm that thalidomide is active in poor-prognosis MM patients such as those relapsing after autologous SCT, and could thus deserve further testing in combination therapy.

AB - Background and Objectives. The introduction of high-dose therapy with stem cell support has significantly improved the outcome of patients with multiple myeloma (MM) in terms of increased complete remission (CR) rate extended survival both disease-free overall. Few options however are presently available for patients who relapse after single or double autologous stem cell transplantation (SCT). Thalidomide a glutamic acid derivative with anti-angiogenetic properties has been recently proposed as salvage treatment for such patients. The present study was aimed at evaluating thalidomide as single agent therapy for patients who had previously received autologous peripheral blood stem cell transplantation. Design Methods. From October 1999 to August 2000 11 patients (7 males/4 females) who had relapsed after single (n=4) or double (n=7) autologous peripheral blood SCT were enrolled in the trial. Thalidomide always employed as a single agent was initially administered at a dose of 100 mg/day; if well tolerated the dose was increased serially by 200 mg every other week to a maximum of 800 mg/day. Results. The median administered dose was 600 mg/day. WHO grade > II toxic effects were constipation lethargy leukopenia. Four patients (36%) showed > 50% reduction in serum M protein concentration 4 showed > 25% reduction for a total response rate averaging 72%. After a median follow-up of 5 months 3 out of 8 responding patients are alive and progression-free and 5 patients have relapsed. Interpretation and Conclusions. These data confirm that thalidomide is active in poor-prognosis MM patients such as those relapsing after autologous SCT, and could thus deserve further testing in combination therapy.

KW - Autologous stem cell transplantation

KW - Multiple myeloma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0035024063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035024063&partnerID=8YFLogxK

M3 - Article

C2 - 11325648

AN - SCOPUS:0035024063

VL - 86

SP - 409

EP - 413

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 4

ER -